Sun Q2 would be the same as just reported CPH Q3.
Getting a handle on Absorica sales in the US is now complicated by having three Absorica products, Absorica, Absorica LD and the very recently launched Generic AG.
I recall that CPH has royalties on two of these but not on LD.
Sun reported that they have increased their sales force for Absorica in the US.
In its Q2 /21 Transcript, Sun reported the following re Absorica..
It will depend on how you want to look at the overall business.
One way to look at is say about a year ago when we were only marketing Absorica, we had roughly -- and I'm rounding it off, we had roughly like a 7% share of market.
And then we launched Absorica LD, and a few months ago we launched the authorized generic of Absorica also.
Now if you look at all three products put together, or three forms of the product book together then our market share is more or less the same."
Its clear from this that Absorica sales are increasing .
What is not clear is how much of the decline in Absorica is offset by growth in the other two.
Generic AG was only launced in Late April 2021, so it had little chance for market share penetration in Q3.
Going forward, we should see gains in Absorica AG sales progressively pick up the slack in the declines in Absorica sales.
How much remains to be seen..